A case of self-limited drug induced liver injury under treatment with elexacaftor/tezacaftor/ivacaftor: When it is worth taking the risk-Reference-Cited by-同舟云学术

A case of self-limited drug induced liver injury under treatment with elexacaftor/tezacaftor/ivacaftor: When it is worth taking the risk

Published:2021-07 Issue:4 Volume:20 Page:712-714
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Stylemans Dimitri^ORCID,François Silke,Vincken Stefanie,Verbanck Sylvia^ORCID,Vanderhelst Eef

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference6 articles.

1. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial;Heijerman;Lancet,2019

2. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele;Middleton;N Engl J Med,2019

3. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases;Cystic Fibrosis Agents,2012

4. European Medicine Agency. Summary of product characteristics (Kaftrio®). https://www.ema.europa.eu/en/documents/product-information/kaftrio-epar-product-information_en.pdf. Accessed on 10 January 2021.

5. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel: Chair:; Panel members; EASL Governing Board representative:. EASL Clinical Practice Guidelines: Drug-induced liver injury;J Hepatol,2019

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathophysiology of Cystic Fibrosis Liver Disease;Pediatric Pulmonology;2024-08-06

2. Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment;Scientific Reports;2024-07-29

3. Effets indésirables de l’association tezacaftor/ivacaftor/elexacaftor pouvant mener à un arrêt de traitement : à propos d’une série de 10 cas;Therapies;2024-07

4. Macroenzymes as a reason for aminotransferases flare in cystic fibrosis patients on CFTR modulators therapy – Report of three cases;Heliyon;2024-05

5. Elexacaftor/Tezacaftor/Ivacaftor use in Pediatric Cystic Fibrosis Patients with Advanced Liver Disease;Journal of Cystic Fibrosis;2024-04